XL-413

From Wikipedia, the free encyclopedia
XL-413
XL-413 structure.png
Identifiers
  • 8-chloro-2-[(2R)-pyrrolidin-2-yl]-3H-[1]benzofuro[3,2-d]pyrimidin-4-one
PubChem CID
ChemSpider
ChEBI
Chemical and physical data
FormulaC14H12ClN3O2
Molar mass289.71 g·mol−1
3D model (JSmol)
  • C1C[C@@H](NC1)C2=NC3=C(C(=O)N2)OC4=C3C=C(C=C4)Cl
  • InChI=1S/C14H12ClN3O2/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9/h3-4,6,9,16H,1-2,5H2,(H,17,18,19)/t9-/m1/s1
  • Key:JJWLXRKVUJDJKG-SECBINFHSA-N

XL-413 is a drug which acts as a selective inhibitor of the enzyme cell division cycle 7-related protein kinase (CDC7). It is being researched for the treatment of some forms of cancer, and also has applications in genetic engineering.[1][2][3][4]

References[edit]

  1. ^ Koltun ES, Tsuhako AL, Brown DS, Aay N, Arcalas A, Chan V, et al. (June 2012). "Discovery of XL413, a potent and selective CDC7 inhibitor". Bioorganic & Medicinal Chemistry Letters. 22 (11): 3727–31. doi:10.1016/j.bmcl.2012.04.024. PMID 22560567.
  2. ^ Sasi NK, Tiwari K, Soon FF, Bonte D, Wang T, Melcher K, et al. (2014). "The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds". PLOS ONE. 9 (11): e113300. Bibcode:2014PLoSO...9k3300S. doi:10.1371/journal.pone.0113300. PMC 4239038. PMID 25412417.
  3. ^ Jin S, Ma H, Yang W, Ju H, Wang L, Zhang Z (June 2018). "Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1". Journal of Molecular Medicine. 96 (6): 513–525. doi:10.1007/s00109-018-1636-7. PMID 29713760. S2CID 14036264.
  4. ^ Wienert B, Nguyen DN, Guenther A, Feng SJ, Locke MN, Wyman SK, et al. (April 2020). "Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair". Nature Communications. 11 (1): 2109. Bibcode:2020NatCo..11.2109W. doi:10.1038/s41467-020-15845-1. PMC 7193628. PMID 32355159.